IQVIA Holdings Inc. $IQV Stock Holdings Raised by Czech National Bank

Key Points

• The Czech National Bank increased its stake in IQVIA Holdings Inc. by 4.5% during Q2, owning a total of 40,172 shares valued at $6.33 million after purchasing an additional 1,747 shares.
• IQVIA reported earnings per share (EPS) of $2.81 for its last quarter, exceeding expectations, with a revenue of $4.02 billion, indicating a 5.3% increase year-over-year.
• Analysts have set a significantly high average price target of $229.64 for IQVIA, with most analysts rating the stock as a Moderate Buy.

Czech National Bank lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,172 shares of the medical research company's stock after buying an additional 1,747 shares during the quarter. Czech National Bank's holdings in IQVIA were worth $6,331,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. American National Bank & Trust purchased a new stake in shares of IQVIA during the 1st quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC lifted its position in shares of IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new stake in shares of IQVIA during the 1st quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. lifted its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on IQV shares. Barclays boosted their price objective on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Truist Financial upped their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price target on shares of IQVIA in a research report on Wednesday, September 3rd. Cowen reiterated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Jefferies Financial Group upgraded shares of IQVIA from a "hold" rating to a "buy" rating and upped their price target for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Trading Down 1.5%

Shares of IQV stock traded down $2.91 during mid-day trading on Friday, reaching $187.29. The company's stock had a trading volume of 2,104,117 shares, compared to its average volume of 1,124,593. The company's 50 day simple moving average is $184.79 and its 200-day simple moving average is $167.31. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $245.20. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $31.84 billion, a PE ratio of 27.10, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the firm posted $2.64 EPS. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.